RE:The story behind “ The Alström Syndrome Clinical Trials “Again, Kay’s personal history with Alstrm Syndrome provides evidence of the benefits this approach can bring. When Kay and her husband presented an Alstrm-related poster at the World Orphan Drug Conference in 2013, a chance meeting with the CEO of Prometic Life Sciences led the three to debate whether Prometic’s investigational anti-fibrotic compound could form the basis of an effective Alstrm treatment. This encounter led to the first clinical trial for an Alstrm treatment in the UK, with the drug set to trial in Italy soon, too.